Neuro-Oncology Symposium 2024: Targeted Therapy & Immunotherapy in Neuro-Oncology - June 8, 2024

Immunotherapy is a type of treatment that works to stimulate or suppress the immune system to teach the body to fight cancer. Studies in immunotherapy hope to help the immune system recognize and fight abnormal cancer cells that have traditionally suppressed immune responses. UofL’s 2024 Neuro-Oncology Symposium will focus on the developments in immunotherapy in neuro-oncology, current treatments and clinical trials, and the outlook for future brain tumor patient outcomes.
When Jun 08, 2024
from 07:30 AM to 04:00 PM
Where UofL ShelbyHurst Conference Center 450 N Whittington Pkwy, Louisville, KY 40222 + Virtual Option via Zoom
Contact Name
Contact Phone 502.588.7414
Add event to calendarvCal


Target Audience

General practitioners, surgeons, ENTs, nurses, nurse practitioners, radiologists, health techs, oncologists, radiation oncologists, physical therapists, rehabilitation specialists, physiatrists, and neurologists.

Saturday, June 8, 2024

7:30 am
Registration & Breakfast

7:50 am
Welcome by Drs. Sarai & Williams

8:00 am – 9:00 am
Improving Access to Care for Cancer Patients, Q&A
Allie Schaber, APRN

9:00 am – 10:00 am
Rehabilitation: What, Why, When & Where, Q&A
Dr. Megan Nelson

10:00 am – 10:15 am

10:15 am – 11:15 am
Innovative Approaches to Brain Tumor Management, Q&A
Dr. Guneet Sarai

11:15 am – 12:15 pm
KEYNOTE: IDH Inhibitors & Other Targeted Approaches, Q&A
Dr. Rimas Lukas

12:15 pm – 1:00 pm

1:00 pm – 2:00 pm
Gamma Delta T-Cell Trial, Q&A
Dr. Akshitkumar Mistry

2:00 pm – 3:00 pm
Single Cell Analysis of GBM Identifying Potential Immunotherapies, Q&A
Dr. Brian Williams

3:00 pm - 4:00 pm
Urolithin A - A Gut Microbial Ally in Elevating GBM Oncolytic Therapy, Q&A
Dr. Sharmila Nair 

4:00 pm

Course Directors
 Guneet Sarai, MD, FACP
Assistant Professor of Medicine and Neurosurgery
UofL Health - Brown Cancer Center
Louisville, KY

 Brian Williams, MD
Director of Brain Tumor Program
Neurosurgery Residency Program Co-Director
Associate Professor Neurosurgery
Department of Neurological Surgery
University of Louisville School of Medicine

Participating Faculty
Rimas Lukas, MD

Associate Professor
Associate Chief of the Neuro-Oncology Division
Lou and Jean Malnati Brain Tumor Institute
Regional Ambulatory Medical Director, Neurology
Department of Neurology
Northwestern University
Evanston, IL

Akshitkumar Mistry, MD
Assistant Professor
Specialty: Brain Tumor Program
Department of Neurosurgery
University of Louisville
Louisville, KY

Sharmila Nair, PhD
Assistant Professor
Department of Microbiology & Immunology, Clinical & Translational Research
University of Louisville
Louisville, KY

Megan Nelson, MD
Associate Professor
Specialty: Cancer Rehabilitation
Department of Neurosurgery
Division of Physical Medicine & Rehabilitation
University of Louisville
Louisville, KY

Alexandra Schaber, APRN
Nurse Practitioner
Brain Tumor Program
University of Louisville
Louisville, KY

Learning Objectives

As a result of participating in this activity, participants should be able to:

1. Discuss the appropriate referral to neuro-oncology with their patients.
2. Identify how targeted therapy and immunotherapy may play a role in treatment for neuro-oncology patients.
3. Identify and discuss trends and future treatment options for brain tumors treated with targeted therapy and immunotherapy.
4. Name some of the new developments to manage gliomas and identify how IDH inhibitors can change the management of gliomas.

Continuing Education Credit
 Physician Credit
- The University of Louisville Continuing Medical Education office designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse - This program has been approved by the Kentucky Board of Nursing for 8.4 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1394. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Accreditation Statement
 The University of Louisville School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Special Services

All individuals are encouraged to participate. To request disability arrangements, please contact the  at least 7 days prior to the date of this program. Continuing Medical Education and Professional Development fully complies with the legal requirements of the ADA and the rules and regulations thereof.


for a copy of the course Flyer

Registration Fees:
There is no fee to attend this event. Advance registration is required to allow for event planning.

In-person Conference
CLICK HERE to Register for the Live In-person Conference

Live Webinar

CLICK HERE to Register for the Webinar version of this Conference

An email will be sent to all registrants 1 week prior and again 2 days prior with instructions for webinar sign-in.

We thank our supporting and exhibiting companies for their participation in the "Neuro-Oncology Symposium 2024: Targeted Therapy & Immunotherapy in Neuro-Oncologyy" conference. A final listing of supporters and exhibitors will be available at the meeting.

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Learner Consent Statement
Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.